Here's the regulatory insight that's going to change everything: stop treating each nanoparticle formulation as a novel drug and start treating the platform as a reusable excipient.
The pharmaceutical industry figured this out decades ago with inactive ingredients. Once lactose monohydrate proved safe as a tablet filler, every new drug could use it without repeating safety studies. The excipient does the work. The active ingredient gets the credit. Both reach patients faster.
Nanoparticle platforms should work the same way.
Consider the absurdity: LNP formulation #1 carries mRNA vaccine → full safety package. LNP formulation #2 (nearly identical) carries different mRNA → full safety package again. Same platform, same manufacturing, same biodistribution—but regulatory agencies treat it as a completely novel system.
The regulatory hack hiding in plain sight: establish nanoparticle families as excipient platforms, not drug-specific delivery systems.
The data supports this
approach: - LNPs successfully deliver mRNA (COVID vaccines), siRNA (Patisiran), small molecules (Doxil), and gene-editing tools (CRISPR)
- Core platform safety remains consistent across payload types
- Manufacturing processes scale across different therapeutic cargo
- Biodistribution and clearance mechanisms stay largely unchanged





























